IRCT20120826010664N5 IRCT 2019-12-26 Tehran University of Medical Sciences Magnesium sulfate neuroprotection in preterm infants Evaluation of neuroprotective effects of magnesium sulfate on preterm infants with a gestational age of 32-36 weeks 2019-12-22 anticipated 246 Complete https://irct.ir/trial/41934 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this study, the block randomization method was designed by Stata version 13 software by the epidemiologist. The number of blocks considered is 6. To conceal the random allocation process, 100 treatment cards will be written in sequential order, then the cards will be placed in sealed envelopes. On each envelope, a random 10-digit code will be written with no sequences and a framework that identifies the relevant patient, and only the methodologist will be aware of the code. When the physician announces a patient's eligibility, the methodologist will provide the envelope with the physician, and the treatment will be selected based on the code written in the envelope. 3 Infant immaturity. Intervention 1: Intervention group: One time Intravenous infusion of Magnesium sulfate (made in pasteur institute co, Tehran, Iran) 50% diluted in Ringer lactate serum at a dose of 2 g per hour for 12 hours. Intervention 2: Control group: Without intervention (Receiving routine cares including only control of labor progress and fetal heart rate monitoring). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is The research team has not yet made a decision on how the data will be published.